David Heimburger, MD
Radiation Oncology · Traverse City, MINPI 1437172608
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $893 of the $1,107 with a category attached, or 80.7%. Telix Pharmaceuticals accounts for 80.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $915 and has fallen 87.6% since, to $113 in 2024.
Across 9 payments — averaging $122.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Telix Pharmaceuticals$893
- Teleflex LLC$98
- Palette Life Sciences, Inc.$48
- Boston Scientific$33
- Bsn Medical Inc$20
- Bioprotect Medical, Inc.$16
Across 3 payments — averaging $13,404 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$40K
What the payments were for
- Travel & lodging$89381%
- Food & beverage$21419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Telix Pharmaceuticals | 1 | $893 |
| Teleflex LLC | 2 | $98 |
| Palette Life Sciences, Inc. | 2 | $48 |
| Boston Scientific | 2 | $33 |
| Bsn Medical Inc | 1 | $20 |
| Bioprotect Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$893
How this compares
$1,107 in reported general payments places this provider in the 70th percentile of 198 radiation oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 19 | $472 |
| Tamsulosin Hcl | 20 | $398 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Traverse City
- Frank ViciniPontiac$231K
- Thomas BoikeClarkston$171K
- Farzan SiddiquiDetroit$72K
- Daniel WahlAnn Arbor$42K
- Daniel ChangAnn Arbor$38K
- Shruti JollyAnn Arbor$30K
- Brandon ManciniGrand Rapids$30K
- Alvaro MartinezFarmington Hills$24K
- James KaneAnn Arbor$19K
- M Salim SiddiquiDetroit$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.